SEARCH

SEARCH BY CITATION

  • 1
    Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K. and Armitage, R. J., Human IL-17: a novel cytokine derived from T cells. J. Immunol. 1995. 155: 54835486.
  • 2
    Harrington, L. E., Mangan, P. R. and Weaver, C. T., Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 2006. 18: 349356.
  • 3
    Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., Wang, Y. et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005. 6: 11331141.
  • 4
    Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. and Kuchroo, V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006. 441: 235238.
  • 5
    Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D. et al., Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006. 441: 231234.
  • 6
    Matusevicius, D., Kivisakk, P., He, B., Kostulas, N., Ozenci, V., Fredrikson, S. and Link, H., Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999. 5: 101104.
  • 7
    Teunissen, M. B., Koomen, C. W., de Waal Malefyt, R., Wierenga, E. A. and Bos, J. D., Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 1998. 111: 645649.
  • 8
    Wong, C. K., Ho, C. Y., Li, E. K. and Lam, C. W., Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000. 9: 589593.
  • 9
    Chabaud, M., Durand, J. M., Buchs, N., Fossiez, F., Page, G., Frappart, L. and Miossec, P., Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999. 42: 963970.
  • 10
    Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S. et al., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999. 103: 13451352.
  • 11
    Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A. et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002. 8: 500508.
  • 12
    Arend, W. P. and Dayer, J. M., Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995. 38: 151160.
  • 13
    Gabay, C., Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 2002. 2: 135149.
  • 14
    Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M. and Palladino, M. A., Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 1992. 89: 73757379.
  • 15
    van den Berg, W. B., Joosten, L. A., Helsen, M. and van de Loo, F. A., Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 1994. 95: 237243.
  • 16
    Miossec, P., Cytokines in rheumatoid arthritis: is it all TNF-alpha? Cell. Mol. Biol. (Noisy-le-grand) 2001. 47: 675678.
  • 17
    Lubberts, E., Joosten, L. A., Oppers, B., van den Bersselaar, L., Coenen-de Roo, C. J., Kolls, J. K., Schwarzenberger, P. et al., IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. 2001. 167: 10041013.
  • 18
    Stamp, L. K., James, M. J. and Cleland, L. G., Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol. Cell. Biol. 2004. 82: 19.
    Direct Link:
  • 19
    Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K. and Iwakura, Y., IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006. 177: 566573.
  • 20
    Nakae, S., Nambu, A., Sudo, K. and Iwakura, Y., Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003. 171: 61736177.
  • 21
    Bush, K. A., Farmer, K. M., Walker, J. S. and Kirkham, B. W., Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002. 46: 802805.
  • 22
    Lubberts, E., Koenders, M. I., Oppers-Walgreen, B., van den Bersselaar, L., Coenen-de Roo, C. J., Joosten, L. A. and van den Berg, W. B., Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004. 50: 650659.
  • 23
    Wildbaum, G., Nahir, M. A. and Karin, N., Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003. 19: 679688.
  • 24
    Bachmann, M. F., Hengartner, H. and Zinkernagel, R. M., T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. 1995. 25: 34453451.
  • 25
    Chackerian, B., Lowy, D. R. and Schiller, J. T., Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 2001. 108: 415423.
  • 26
    Jegerlehner, A., Tissot, A., Lechner, F., Sebbel, P., Erdmann, I., Kundig, T., Bachi, T. et al., A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002. 20: 31043112.
  • 27
    Ambühl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R Nief, V. et al., A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertension 2006, in press.
  • 28
    Spohn, G., Schwarz, K., Maurer, P., Illges, H., Rajasekaran, N., Choi, Y., Jennings, G. T. and Bachmann, M. F., Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol. 2005. 175: 62116218.
  • 29
    Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A. et al., A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 2005. 35: 20312040.
  • 30
    Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T. et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005. 201: 233240.
  • 31
    Svensson, L., Jirholt, J., Holmdahl, R. and Jansson, L., B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 1998. 111: 521526.
  • 32
    Corthay, A., Johansson, A., Vestberg, M. and Holmdahl, R., Collagen-induced arthritis development requires alpha beta T cells but not gamma delta T cells: studies with T cell-deficient (TCR mutant) mice. Int. Immunol. 1999. 11: 10651073.
  • 33
    Ferretti, S., Bonneau, O., Dubois, G. R., Jones, C. E. and Trifilieff, A., IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol. 2003. 170: 21062112.
  • 34
    Nandakumar, K. S. and Holmdahl, R., Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J. Immunol. Methods 2005. 304: 126136.
  • 35
    Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L. et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003. 421: 744748.
  • 36
    Lubberts, E., The role of IL-17 and family members in the pathogenesis of arthritis. Curr. Opin. Investig. Drugs 2003. 4: 572577.
  • 37
    Touil, T., Fitzgerald, D., Zhang, G. X., Rostami, A. M. and Gran, B., Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis. Drug News Perspect. 2006. 19: 7783.
  • 38
    Chen, Y., Langrish, C. L., McKenzie, B., Joyce-Shaikh, B., Stumhofer, J. S., McClanahan, T., Blumenschein, W. et al., Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006. 116: 13171326.
  • 39
    Hofstetter, H. H., Ibrahim, S. M., Koczan, D., Kruse, N., Weishaupt, A., Toyka, K. V. and Gold, R., Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005. 237: 123130.
  • 40
    Sonderegger, I., Röhn, T. A., Kurrer, M., Iezzi, G., Belladonna, M. L., Kastelein, R. A., Bachmann, M. F. and Kopf, M., Neutralization of IL-17 by active vaccination ameliorates IL-23 mediated autoimmune myocarditis. Eur. J. Immunol, 2006. 36: DOI 10.1002/eji.200636484.
  • 41
    Kolls, J. K. and Linden, A., Interleukin-17 family members and inflammation. Immunity 2004. 21: 467476.
  • 42
    Bowman, E. P., Chackerian, A. A. and Cua, D. J., Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr .Opin. Infect. Dis. 2006. 19: 245252.
  • 43
    Cielens, I., Ose, V., Petrovskis, I., Strelnikova, A., Renhofa, R., Kozlovska, T. and Pumpens, P., Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods. FEBS Lett 2000. 482: 261264.